(Note: not all of these involve PZP. “PZP” is mentioned. Also, “vaccine” and “fertility” are mentioned.)
PAT. NO. Title
1. 8,802,135 Delivery system for remote treatment of an animal
2. 8,524,247 Rabies virus-based recombinant immunocontraceptive compositions and methods of use
3. 8,425,932 Delivery system for remote treatment of an animal
4. 8,057,992 Methods for identifying peptides that bind to intact oocytes
5. 7,731,939 Vaccine compositions and adjuvant
6. 7,056,515 Antigens for immunocontraception
7. 6,172,198 PAPP-A, its immunodetection and uses
. . . Examples of suitable vaccines include, but not limited to, PZP (Porcine Zona Pelucida), Foot and Mouth, Bovine Tuberculosis, Tuberculosis, and other compatible live or attenuated vaccines known to the art to expose a treated animal to pathogenic organisms in a manner that provokes an immune response.
. . . The biologically active agent may also include protein-based agents, such as crude or purified cell lysates, sub-unit vaccines, protein-based antigen display systems, antigens, peptides, oligopeptides, or polypeptides that are absorbable through the skin of the animal when used in combination with a transdermal carrier, for example proteinaceous or glycoprotein-derived contraceptives, such as a zona pellucida based contraceptive, e.g. the Porcine Zona Pellucida (PZP) contraceptive. . . .
. . . Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal . . .
. . . In another preferred form, the biologically active agent is a vaccine or immunogenic compound.
Examples of suitable vaccines include, but not limited to, PZP (Porcine Zona Pelucida), Foot and Mouth, Bovine Tuberculosis, Tuberculosis, and other compatible live or attenuated vaccines known to the art to expose a treated animal to pathogenic organisms in a manner that provokes an immune response. . . .
. . . Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. . . .
. . . Using phage display technology, others selected a human peptide that bound to the human sperm/egg interactive site (5) and used the peptide as an antigen to produce anti-sperm antibodies that prevented conception in mice (6,7). . . .
The immune response of an animal to a target immunogen may be enhanced by use of a novel adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen, and is particularly preferred for use with immunocontraceptive vaccines such as GnRH and PZP immunocontraceptive vaccines. . . .
The present invention provides immunocontraceptive vaccines comprising a zona pellucida (ZP) polypeptide, and/or a variant thereof, from a carnivorous mammal such as cat, dog, ferret or mink. Such vaccines are useful in reducing fertility of cats and/or dogs. . . .
#7. This product (not PZP in this case) is for humans. Quote:
. . . According to tenth aspect of the present invention, there is provided the use of PAPP-A as a target for immunological contraception. Immunological fertility regulation may be achieved by active vaccination against intact PAPP-A or fragments thereof. Active vaccination may be achieved by any of the accepted oral, mucosal or subcutaneous routes (of antigen administration) used to induce an immune response in humans. The PAPP-A antigen may be chemically modified, genetically engineered or the genome inserted into a vector to enhance immungenecity when expressed in the host. . . .
By the way, I’m surprised by certain jargon used in these documents:
. . . the quality of the protein yield was sacrificed. . . .
. . . This mouse was sacrificed 5 days later for hybridoma cell fusion. . . .
. . . and the animal sacrificed five days later. . . .
Value for value. If you appreciate this post, please donate a small amount to encourage more research and commentary.